WO2003020258A1 - Anti-influenza drugs - Google Patents

Anti-influenza drugs Download PDF

Info

Publication number
WO2003020258A1
WO2003020258A1 PCT/JP2002/008940 JP0208940W WO03020258A1 WO 2003020258 A1 WO2003020258 A1 WO 2003020258A1 JP 0208940 W JP0208940 W JP 0208940W WO 03020258 A1 WO03020258 A1 WO 03020258A1
Authority
WO
WIPO (PCT)
Prior art keywords
airway
influenza
drugs
influenza virus
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008940
Other languages
English (en)
French (fr)
Inventor
Hiroshi Kido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Techno Network Shikoku Co Ltd
Original Assignee
Boehringer Ingelheim International GmbH
Techno Network Shikoku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK05101866.4A priority Critical patent/HK1069526B/xx
Priority to KR10-2004-7003276A priority patent/KR20040045429A/ko
Priority to MXPA04002066A priority patent/MXPA04002066A/es
Priority to NZ532019A priority patent/NZ532019A/en
Priority to EP02762982A priority patent/EP1437134A4/en
Priority to IL16053902A priority patent/IL160539A0/xx
Priority to BR0212232-4A priority patent/BR0212232A/pt
Priority to HU0402299A priority patent/HUP0402299A3/hu
Priority to CA002459492A priority patent/CA2459492A1/en
Application filed by Boehringer Ingelheim International GmbH, Techno Network Shikoku Co Ltd filed Critical Boehringer Ingelheim International GmbH
Publication of WO2003020258A1 publication Critical patent/WO2003020258A1/ja
Priority to US10/790,448 priority patent/US20040242700A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2002/008940 2001-09-04 2002-09-03 Anti-influenza drugs Ceased WO2003020258A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU0402299A HUP0402299A3 (en) 2001-09-04 2002-09-03 Anti-influenza drugs containing ambroxol and bromhexine and process for its preparation
KR10-2004-7003276A KR20040045429A (ko) 2001-09-04 2002-09-03 항인플루엔자 약제
MXPA04002066A MXPA04002066A (es) 2001-09-04 2002-09-03 Farmacos contra influenza.
NZ532019A NZ532019A (en) 2001-09-04 2002-09-03 Anti-influenza drugs
EP02762982A EP1437134A4 (en) 2001-09-04 2002-09-03 FLU RESOURCES
HK05101866.4A HK1069526B (en) 2001-09-04 2002-09-03 Anti-influenza drugs
BR0212232-4A BR0212232A (pt) 2001-09-04 2002-09-03 Agente antiinfluenza
IL16053902A IL160539A0 (en) 2001-09-04 2002-09-03 Anti-influenzal agents
CA002459492A CA2459492A1 (en) 2001-09-04 2002-09-03 Anti-influenzal agent
US10/790,448 US20040242700A1 (en) 2001-09-04 2004-02-27 Anti-influenzal agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-267236 2001-09-04
JP2001267236 2001-09-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/790,448 Continuation US20040242700A1 (en) 2001-09-04 2004-02-27 Anti-influenzal agent

Publications (1)

Publication Number Publication Date
WO2003020258A1 true WO2003020258A1 (en) 2003-03-13

Family

ID=19093396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008940 Ceased WO2003020258A1 (en) 2001-09-04 2002-09-03 Anti-influenza drugs

Country Status (11)

Country Link
US (1) US20040242700A1 (ja)
EP (1) EP1437134A4 (ja)
KR (1) KR20040045429A (ja)
CN (1) CN1267091C (ja)
BR (1) BR0212232A (ja)
CA (1) CA2459492A1 (ja)
HU (1) HUP0402299A3 (ja)
IL (1) IL160539A0 (ja)
MX (1) MXPA04002066A (ja)
NZ (1) NZ532019A (ja)
WO (1) WO2003020258A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
ITMI20032463A1 (it) * 2003-12-16 2005-06-17 Advance Holdings Ltd Soluzione acquosa concentrata a base di ambroxolo
BRPI0614887A2 (pt) * 2005-08-25 2011-04-19 Boehringer Ingelheim Int uso de ambroxol para o tratamento de infecções por rinovìrus
EP2138172A4 (en) * 2007-03-19 2010-04-28 Yuuzou Tsuchida ANTIVIRAL ACTIVE SUBSTANCE
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
EP3654960A1 (en) 2017-07-16 2020-05-27 Neuere, LLC Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
JP7369716B2 (ja) 2018-01-26 2023-10-26 ノイレ, エルエルシー 皮膚バリア機能を改善するためのアンブロキソールの使用
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
WO2021255129A1 (en) * 2020-06-16 2021-12-23 Spedding Research Solutions, Sas Novel use of a modulator of glucosylceramide degradation for viral infections
CN118660866A (zh) 2021-10-28 2024-09-17 启威公司 治疗用改良型氨溴索
CN121127451A (zh) 2023-05-02 2025-12-12 启威公司 一种用于医疗用途的改良型氨溴索

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
JPH06287144A (ja) * 1993-02-03 1994-10-11 Takeda Chem Ind Ltd かぜ薬製剤
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610997A1 (de) * 1986-04-02 1987-10-15 Krewel Werke Gmbh Ambroxol-nasenspray
JPH11510168A (ja) * 1995-07-28 1999-09-07 ザ、プロクター、エンド、ギャンブル、カンパニー 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法
US5648358A (en) * 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
JPH06287144A (ja) * 1993-02-03 1994-10-11 Takeda Chem Ind Ltd かぜ薬製剤
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] NISHIKAWA M. ET AL.: "Ambroxol suppresses influenza virus multiplication in the airway by increasing antiviral factor levels", XP002961052, accession no. STN Database accession no. 2002:542180 *
DATABASE CAPLUS [online] YANG B. ET AL.: "Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels", XP002961053, accession no. STN Database accession no. 2002:444958 *
EUROPEAN RESPIRATORY JOURNAL, vol. 19, no. 5, 2002, pages 952 - 958 *
See also references of EP1437134A4 *
TOKUSHIMA IGAKKAI, vol. 58, no. 3, 2002, pages 162 - 167 *

Also Published As

Publication number Publication date
HUP0402299A3 (en) 2008-04-28
HUP0402299A2 (hu) 2005-02-28
HK1069526A1 (en) 2005-05-27
EP1437134A4 (en) 2009-03-11
CN1267091C (zh) 2006-08-02
MXPA04002066A (es) 2005-02-17
BR0212232A (pt) 2004-10-05
NZ532019A (en) 2007-04-27
CN1549708A (zh) 2004-11-24
EP1437134A1 (en) 2004-07-14
KR20040045429A (ko) 2004-06-01
CA2459492A1 (en) 2003-03-13
IL160539A0 (en) 2004-07-25
US20040242700A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2003020258A1 (en) Anti-influenza drugs
ATE276244T1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
SI1435915T1 (sl) Oralne dozirne oblike za propiverin ali njegove farmacevtsko sprejemljive soli s podaljšanim sproščanjem učinkovine
NO20016369D0 (no) Respiratorisk syncytialvirus-replikasjonsinhibitorer
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
ATE392863T1 (de) Streifen zur abgabe eines mundpflegewirkstoffes
NO20016370L (no) Respiratorisk syncytialvirus-replikasjonsinhibitorer
EA200400481A1 (ru) Применение флибансерина для лечения половых расстройств
DK1572153T3 (da) Fremstilling af sterile vandige suspensioner, som omfatter mikroniserede krystallinske virksomme stoffer til inhalering
AR030829A1 (es) Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
MXPA03009391A (es) METODO PARA FABRICAR UNA COMPOSICIoN FARMACEUTICA DE DOSIS BAJA.
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DK1957037T3 (da) Farmaceutisk præparat til nasal anvendelse af fentanyl
ATE240717T1 (de) Wässrige formulierung zur nasalen verabreichung
BRPI0411623A (pt) forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo
EA200600603A1 (ru) Оральная система доставки лекарственного препарата
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
WO2005051350A3 (en) Water dispersible tablet
WO2005065639A3 (en) Novel pharmaceutical compositions
ECSP014082A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
WO2008020314A3 (en) Statin stabilizing dosage formulations
WO2006071896A3 (en) Epitope-based sars vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160539

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10790448

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 20028170601

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002066

Country of ref document: MX

Ref document number: 2459492

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047003276

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002328415

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 532019

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002762982

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002762982

Country of ref document: EP